Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 19/20 | 0.75 |
| ▸ | MAPK10 | P53779 | 17/20 | 0.75 |
| ▸ | MAPK8 | P45983 | 16/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3791888 | 0.89 | MAPK9 (0.75) | MAPK9MAPK10MAPK8MAPK1 | |
| SCHEMBL3776306 | 0.86 | MAPK9 (1.00) | MAPK9MAPK10MAPK8MAPK1 | |
| SCHEMBL3778162 | 0.82 | MAPK10 (0.72) | MAPK9MAPK10MAPK8MAPK1 | |
| SCHEMBL16868752 | 0.79 | MAPK9 (0.63) | MAPK9MAPK10MAPK8MAPK1 | |
| SCHEMBL3711672 | 0.77 | MAPK8 (0.79) | MAPK9MAPK10MAPK8MAPK1 | |
| SCHEMBL14787960 | 0.76 | MAPK8 (0.56) | MAPK9MAPK10MAPK8 | |
| SCHEMBL3783257 | 0.76 | MAPK9 (1.00) | MAPK9MAPK10MAPK8MAPK1 | |
| SCHEMBL3783200 | 0.75 | MAPK9 (1.00) | MAPK9MAPK10MAPK8MAPK1 | |
| SCHEMBL3782088 | 0.75 | MAPK9 (1.00) | MAPK9MAPK10MAPK8MAPK1 | |
| SCHEMBL3782905 | 0.74 | MAPK8 (0.72) | MAPK9MAPK10MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190231751-A1 | TREATMENT OF FIBROTIC DISORDERS WITH JUN N-TERMINAL KINASE INHIBITORS | IMAGO PHARMACEUTICALS, INC. | 2019-08-01 | — | — | US | claimed |
| EP-3509586-A1 | TREATMENT OF FIBROTIC DISORDERS WITH JUN N-TERMINAL KINASE INHIBITORS | Imago Pharmaceuticals, Inc. (US) | 2019-07-17 | — | — | EP | claimed |
| WO-2018049353-A1 | TREATMENT OF FIBROTIC DISORDERS WITH JUN N-TERMINAL KINASE INHIBITORS | IMAGO PHARMACEUTICALS, INC. (US) | 2018-03-15 | — | — | WO | claimed |
| EP-2393806-B1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARM INC (US) | 2017-10-25 | — | — | EP | claimed |
| US-9073891-B2 | Inhibitors of Jun N-terminal kinase | IMAGO PHARMACEUTICALS, INC. (US) | 2015-07-07 | — | — | US | claimed |
| US-8450363-B2 | Inhibitors of Jun N-terminal kinase | ELAN PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | claimed |
| US-20130072494-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARMACEUTICALS, INC. | 2013-03-21 | — | — | US | claimed |
| EP-2393806-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | Elan Pharmaceuticals Inc. (US) | 2011-12-14 | — | — | EP | claimed |
| US-20100331335-A1 | Inhibitors of Jun N-Terminal Kinase | ELAN PHARMACETICALS, INC. | 2010-12-30 | — | — | US | claimed |
| WO-2010091310-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | claimed |
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| US-20200277285-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-20200039972-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20190231751-A1 | TREATMENT OF FIBROTIC DISORDERS WITH JUN N-TERMINAL KINASE INHIBITORS | IMAGO PHARMACEUTICALS, INC. | 2019-08-01 | — | — | US | disclosed |
| EP-3509586-A1 | TREATMENT OF FIBROTIC DISORDERS WITH JUN N-TERMINAL KINASE INHIBITORS | Imago Pharmaceuticals, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| US-8450363-B2 | Inhibitors of Jun N-terminal kinase | ELAN PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20130072494-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARMACEUTICALS, INC. | 2013-03-21 | — | — | US | disclosed |
| EP-2393806-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | Elan Pharmaceuticals Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100331335-A1 | Inhibitors of Jun N-Terminal Kinase | ELAN PHARMACETICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2010091310-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039972-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK9 16/4885MAPK10 21/4885MAPK8 24/4885 |
| US-20190231751-A1 | TREATMENT OF FIBROTIC DISORDERS WITH JUN N-TERMINAL KINASE INHIBITORS | MAP3K20, MYLK2, MAP3K8 | MAPK9 67/4885MAPK10 33/4885MAPK8 28/4885 |
| US-20130072494-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK9 16/4885MAPK10 21/4885MAPK8 24/4885 |
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK9 16/4885MAPK10 21/4885MAPK8 24/4885 |
| US-20200277285-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK9 16/4885MAPK10 21/4885MAPK8 24/4885 |
| US-20100331335-A1 | Inhibitors of Jun N-Terminal Kinase | CHUK, MAPK6, MAPK3 | MAPK9 16/4885MAPK10 21/4885MAPK8 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.